Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|February 14, 2019
Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutationOu Yamaguchi, Kyoichi Kaira, Atsuto Mouri, et al.
Thoracic Cancer|February 1, 2021
Effectiveness of EGFR-TKI rechallenge immediately after PD-1 blockade failureKyoichi Kaira, Kunihiko Kobayashi, Ayako Shiono, et al.
Cancer Chemotherapy and Pharmacology|August 25, 2019
Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancerAtsuto Mouri, Kyoichi Kaira, Ou Yamaguchi, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 19, 2024
Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancerKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Scientific Reports|September 15, 2020
Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50Ou Yamaguchi, Kyoichi Kaira, Kosuke Hashimoto, et al.
Journal of Clinical Medicine|March 12, 2020
Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung CancerKosuke Hashimoto, Kyoichi Kaira, Ou Yamaguchi, et al.
Respiratory Medicine Case Reports|December 24, 2025
G-CSF-producing pulmonary sarcomatoid carcinoma treated with chemoradiotherapy followed by durvalumab: a case reportNaohito Hashimoto, Kyoichi Kaira, Tatsuhiko Uno, et al.
Cancer Immunology, Immunotherapy : CII|December 19, 2025
Th7R predicts chemo-immunotherapy response and survival in small cell lung cancerShota Takei, Ayako Shiono, Satoshi Yamasaki, et al.
Scientific Reports|May 12, 2026
Early FMISO PET changes as exploratory predictors of immune checkpoint inhibitor response in advanced lung cancer: a pilot studyKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 18, 2022
Prognostic Potential of Metabolic Activity on 18 F-FDG Accumulation in Advanced NSCLC Receiving Combining Chemotherapy Plus PD-1 BlockadeKosuke Hashimoto, Kyoichi Kaira, Hisao Imai, et al.
Pageof 10